Additional Hetero Ring Containing Patents (Class 546/187)
-
Publication number: 20040048843Abstract: Disclosed are novel compounds of the formula 1Type: ApplicationFiled: April 16, 2003Publication date: March 11, 2004Applicant: Schering CorporationInventors: Pauline C. Ting, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom, Qingbei Zeng
-
Publication number: 20040044044Abstract: Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: ApplicationFiled: July 30, 2003Publication date: March 4, 2004Applicant: Amgen Inc.Inventors: Benny C. Askew, Frenel F. De Morin, Andrew Hague, Ellen Laber, Aiwen Li, Gang Liu, Patricia Lopez, Rana Nomak, Vincent Santora, Christopher Tegley, Kevin Yang
-
Patent number: 6699880Abstract: This invention relates to the compounds represented by the general formula [I], [in which A—D signify optionally substituted methine group(s) or nitrogen atom; E signifies oxygen or sulfur atom; signify optionally substituted mono- or bi-cyclic aliphatic nitrogen-containing heterocyclic group(s); R1 signifies lower alkenyl, lower alkynyl, cyclo(lower alkyl), lower alkanoyl, lower alkoxycarbonyl, optionally substituted lower alkyl and the like; and R2 signifies lower alkyl].Type: GrantFiled: April 15, 2002Date of Patent: March 2, 2004Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Takeru Yamakawa, Makoto Ando, Seita Koito, Kenji Ohwaki, Toshifumi Kimura, Toshihiko Saeki, Mitsuru Miyaji, Yuki Iwahori, Toru Fujikawa, Norikazu Otake, Kazuhito Noguchi
-
Patent number: 6696570Abstract: Oligomeric compounds and methods of making the compound having the formula: T—&Parenopenst;E—F&Parenclosest;i—&Parenopenst;E—F′&Parenclosest;j—&Parenopenst;E′—F&Parenclosest;k—&Parenopenst;E′—F′&Parenclosest;l—S (II) wherein i, j, k, and l are integers from about 0 to 300 and the sum of i, j, k, and l is greater than 2, wherein the units F, F′ and T are derived from one or more multi-functional carbonyl compounds of general structure DO—CO—CRaRb—(—CRcRd—)n—NH—(Y)m—CO—OD (IV) wherein n is an integer from 1 to 15, m is either 0 or 1; Ra, Rb, Rc, and Rd, are each a hydrogen or a hydrocarbyl group; Y is CO—(CReRf)p, wherein Re and Rf are each a hydrogen or hydrocarbyl group and p is zero or an integer from 1 to 20 or CO—C6H4—, wherein the substitution pattern on the phenylene group is an ortho, meta, or para substitution pattern, andType: GrantFiled: October 25, 2001Date of Patent: February 24, 2004Assignee: Cytec Technology Corp.Inventors: Thomas P. Sassi, Ram. B. Gupta
-
Publication number: 20040034229Abstract: Disclosed are compounds of the formula (I) 1Type: ApplicationFiled: October 11, 2002Publication date: February 19, 2004Applicant: Schering CorporationInventors: Arthur G. Taveras, Michael Dwyer, Johan A. Ferreira, Viyyoor M. Girijavallabhan, Jianping Chao, John J. Baldwin, J. Robert Merritt, Ge Li
-
Patent number: 6689794Abstract: This invention is directed to aromatic sulfone hydroxamates (also known as “aromatic sulfone hydroxamic acids”) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.Type: GrantFiled: May 10, 2002Date of Patent: February 10, 2004Assignee: Pharmacia CorporationInventors: John N. Freskos, Yvette M. Fobian, Thomas E. Barta, Daniel P. Becker, Louis J. Bedell, Terri L. Boehm, Jeffery N. Carroll, Gary A. DeCrescenzo, Susan L. Hockerman, Darren J. Kassab, Steve A. Kolodziej, Joseph McDonald, Deborah A. Mischke, Monica B. Norton, Joseph G. Rico, John J. Talley, Clara I. Villamil, Lijuan Jane Wang
-
Publication number: 20040024217Abstract: In its several embodiments, this invention discloses novel processes to prepare the compounds of formula II and formula IV: 1Type: ApplicationFiled: March 27, 2003Publication date: February 5, 2004Applicant: Schering CorporationInventors: William Leong, Minzhang Chen, Bosco A. D'sa, Man Zhu, Tong Xiao, Xiongwei Shi, Suhan Tang, Dinesh Gala, Andrew J. Goodman, Christopher M. Nielsen, Gary M. Lee, Juan A. Gamboa, Andrew D. Jones
-
Patent number: 6686357Abstract: Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.Type: GrantFiled: October 30, 2000Date of Patent: February 3, 2004Assignee: Pfizer, Inc.Inventors: Martin J. Wythes, Michael J. Palmer, Mark I. Kemp, Malcolm C. MacKenny, Robert J. Maguire, James F. Blake, Jr.
-
Patent number: 6686362Abstract: Compounds of formula (I) in which R1, R2, R3 and R4 have the meanings given in the specification, are receptor tyrosine kinase inhibitors useful in the treatment of proliferative disorders, such as cancer.Type: GrantFiled: December 20, 2002Date of Patent: February 3, 2004Assignee: Theravance, Inc.Inventors: John H. Griffin, Roger Briesewitz, Jonathan W. Wray
-
Patent number: 6683093Abstract: This invention is directed to aromatic sulfone hydroxamates (also known as aromatic sulfone hydroxamic acids) and salts thereof that, inter alia, tend to inhibit matrix metalloproteinase (also known as matrix metalloprotease or MMP) activity and/or aggrecanase activity. This invention also is directed to a treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP activity and/or aggrecanase activity.Type: GrantFiled: November 21, 2001Date of Patent: January 27, 2004Assignee: Pharmacia CorporationInventors: Thomas E. Barta, Daniel P. Becker, Louis J. Bedell, Terri L. Boehm, Jeffery N. Carroll, Gary A. DeCrescenzo, Yvette M. Fobian, John N. Freskos, Daniel P. Getman, Joseph J. McDonald, Madeleine H. Li, Susan L. Hockerman, Carol Pearcy Howard, Steve A. Kolodziej, Deborah A. Mischke, Joseph G. Rico, Nathan W. Stehle, Michael B. Tollefson, William F. Vernier, Clara I. Villamil, Darren J. Kassab
-
Publication number: 20040010008Abstract: The present invention provides a compound of the formula 1Type: ApplicationFiled: August 28, 2002Publication date: January 15, 2004Applicant: Schering CorporationInventors: Anandan Palani, Michael W. Miller, Jack D. Scott
-
Publication number: 20040006080Abstract: The present invention provides a compound of a formula (I): 1Type: ApplicationFiled: January 13, 2003Publication date: January 8, 2004Applicant: AstraZeneca AB, a Sweden corporationInventors: Aaron Rigby, Hitesh Sanganee, Brian Springthorpe, Louise Lawrence
-
Patent number: 6660858Abstract: The present invention relates to novel 2-aminobenzoxazole derivative compounds of the following formula: wherein R1 to R4 and Z have the meanings provided herein. The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing 2-aminobenzoxazole derivative compounds.Type: GrantFiled: March 28, 2001Date of Patent: December 9, 2003Assignee: Lion Bioscience AGInventors: Scott C. Sutton, Amy L. Hannah, Yuewu Chen, Shirong Zhu
-
Publication number: 20030225102Abstract: The invention discloses a novel series of compound represented by general formula (I), 1Type: ApplicationFiled: April 8, 2003Publication date: December 4, 2003Applicant: TORRENT PHARMACEUTICALS LTD.Inventor: Alangudi Sankaranarayanan
-
Publication number: 20030225060Abstract: Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.Type: ApplicationFiled: February 3, 2003Publication date: December 4, 2003Inventors: Feroze Ujjainwalla, Lin Chu, Mark T. Goulet, Bonnie Louridas, Matthew J. Wyvratt, Daniel Warner
-
Patent number: 6653478Abstract: The invention is directed to substituted benzimidazol-2-ones of Formula I, wherein A, X, Y, m, n, R1, R2, R3, R4, and R5 are as described in the specification, which are useful as vasopressin receptor antagonists or Neuropeptide Y Modulators for treating conditions such as aggression, obsessive-compulsive disorders, hypertension, dysmenorrhea, congestive heart failure/cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, edema, ischemia, stroke, thrombosis, water retention, nephrotic syndrome, central nervous injuries, obesity, anorexia, hyperglycemia, diabetes, anxiety, depression, asthma, memory loss, sexual dysfunction, disorders of sleep and other circadian rhythms, and Cushing's disease.Type: GrantFiled: October 23, 2001Date of Patent: November 25, 2003Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Maud J. Urbanski, Joseph W. Gunnet, Jr., Keith T. Demarest
-
Publication number: 20030216433Abstract: (S)-4-Amino-5-chloro-2-methoxy-N-[-[1 -(2-tetrahydrofurylcarbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide of the following formula (I): 1Type: ApplicationFiled: December 18, 2002Publication date: November 20, 2003Inventors: Shiro Kato, Hiroshi Yamazaki, Yoshimi Hirokawa, Yoko Kan, Naoyuki Yoshida, Kazuo Morikage, Yukiko Morikage
-
Patent number: 6649771Abstract: A pyrrolotriazole compound of the following formula (I), and a silver halide color photographic light-sensitive material containing the pyrrolotriazole compound as a cyan coupler: wherein R1 and R2 each independently are an alkyl, cycloalkyl, alkenyl, aryl or heterocyclic group, provided that R1 and R2 may bond together to form a 5- or 6-membered nitrogen-containing heterocycle; R3 is an alkyl, cycloalkyl, alkenyl, aryl or heterocyclic group; R4 is an alkyl, cycloalkyl, alkenyl, alkoxy or amino group; R5 is a hydrogen atom, an alkyl or aryl group; R6 is an alkyl, cycloalkyl or alkenyl group; and X is an oxygen or sulfur atom.Type: GrantFiled: March 26, 2001Date of Patent: November 18, 2003Assignee: Fuji Photo Film Co., Ltd.Inventors: Takeshi Nakamine, Nobuo Seto, Hideaki Sato, Yasuaki Deguchi
-
Patent number: 6645957Abstract: The invention relates to compounds represented by the following general formula (1): wherein A is an aromatic compound which may be substituted, or the like, B is a nitrogen atom or CH, X is a lower alkylene group which may be substituted, or the like, Y is a single bond or the like; Z is a divalent residue of benzene which may be substituted, or the like, and m and n are independently an integer of 1 to 4, and medicines comprising such a compound. These compounds have an excellent inhibitory effect on the production of an IgE antibody and are hence useful as antiallergic agents and the like.Type: GrantFiled: June 19, 2002Date of Patent: November 11, 2003Assignee: Kowa Co., Ltd.Inventors: Hiroyuki Ishiwata, Seiichi Sato, Mototsugu Kabeya, Soichi Oda, Yukio Hattori, Makoto Suda, Manabu Shibasaki, Hiroshi Nakao, Takao Nagoya
-
Publication number: 20030207917Abstract: The present invention discloses compounds, which are novel muscarinic receptor antagonists, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such muscarinic receptor antagonists as well as methods for using them to treat cognitive disorders such as Alzheimer's disease.Type: ApplicationFiled: October 8, 2002Publication date: November 6, 2003Applicant: Schering CorporationInventors: Yuguang Wang, Samuel Chackalamannil
-
Patent number: 6642228Abstract: There are provided compounds represented by the general formula (I): [wherein Ar is indole etc., R1 is hydrogen etc., B is bond, or B—N—R1 forms a ring structure and is piperidine etc., n is 0, 1, etc., A is trimethylene, butylene, etc., Q is piperidine, isoindoline, etc.], or pharmacologically acceptable acid addition salts thereof, and &agr;1B adrenoceptor antagonists composed of these substances. The invented compounds are antagonists having high affinity for &agr;1B adrenoceptor and are useful as pharmaceutical agents for use in prophylaxis/therapy of diseases (e.g., hypertension) in which &agr;1B adrenoceptor is involved or as pharmacological tools for elucidation of physiological activities mediated by &agr;1B adrenoceptor.Type: GrantFiled: April 13, 2001Date of Patent: November 4, 2003Assignee: Toray Industries, Inc.Inventors: Ryoji Hayashi, Eiji Ohmori, Masafumi Isogaya, Mitsuhiro Moriwaki, Hiroki Kumagai
-
Patent number: 6638967Abstract: Compounds of Formula I Wherein Z2 is an Oxygen or a Sulfur, Z1 is —CH═CH— and Y is a bond, W1 and W2 are hydrogens and X1 and X2 are various heterocyclic rings are disclosed.Type: GrantFiled: August 6, 2001Date of Patent: October 28, 2003Assignee: Ortho-McNeil Phamraceutical, Inc.Inventors: Michael Bogenstaetter, Wenying Chai, Annette K. Kwok
-
Publication number: 20030199519Abstract: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.Type: ApplicationFiled: April 5, 2002Publication date: October 23, 2003Applicant: IMMUNOGEN INC.Inventors: Robert Yongxin Zhao, Ravi V.J. Chari
-
Patent number: 6635640Abstract: The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.Type: GrantFiled: June 29, 2001Date of Patent: October 21, 2003Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Chung Chen Wei, Ping Huang, Jingrong Cui
-
Publication number: 20030191112Abstract: A novel class of substituted piperidines, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.Type: ApplicationFiled: October 9, 2002Publication date: October 9, 2003Inventor: Florencio Zaragoza Dorwald
-
Publication number: 20030187255Abstract: Pharmaceutical compositions containing novel therapeutic heterocycles for use in diseases in which an NK2 receptor is implicated, processes for preparing and methods for using the same.Type: ApplicationFiled: August 30, 2002Publication date: October 2, 2003Inventor: Scott Carson Miller
-
Patent number: 6627629Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.Type: GrantFiled: June 29, 2001Date of Patent: September 30, 2003Assignee: Bristol-Myers Squibb PharmaInventors: Soo S. Ko, James R. Pruitt, Dean A. Wacker, Douglas G. Batt
-
Patent number: 6610737Abstract: Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of &Dgr;6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain inflammatory disorders and chronic degenerative diseases characterized by neuronal loss and chronic pain including neuropathic pain.Type: GrantFiled: November 26, 2002Date of Patent: August 26, 2003Assignee: Pharmos CorporationInventors: Aaron Garzon, George Fink
-
Patent number: 6610707Abstract: Compounds of the formula: wherein R1, Y, W, A and R2 are as defined above are inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases and nerve damage.Type: GrantFiled: September 1, 1999Date of Patent: August 26, 2003Assignee: Pfizer Inc.Inventors: David John Bull, Robert John Maguire, Michael John Palmer, Martin James Wythes
-
Patent number: 6608090Abstract: The instant invention provides novel benzothiophene compounds for use in treating skeletal diseases.Type: GrantFiled: April 21, 1995Date of Patent: August 19, 2003Assignee: Eli Lilly and CompanyInventors: Michelle L. Bourgeois, Jeffrey A. Dodge, Charles D. Jones
-
Publication number: 20030153573Abstract: This invention concerns the compounds of formula 1Type: ApplicationFiled: November 19, 2002Publication date: August 14, 2003Inventors: Jean-Paul Rene Marie Bosmans, Christopher John Love, Marc Gustaaf Celine Verdonck, Joannes Adrianus Jacobus Schuurkes
-
Patent number: 6602885Abstract: The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is H, alkyl or alkenyl; R2 is optionally substituted phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, naphthyl, fluorenyl or diphenylmethyl; R3 is optionally substituted phenyl, heteroaryl or naphthyl; R4 is H, alkyl, fluoro-alkyl, cyclopropylmethyl, —CH2CH2OH, —CH2CH2—O-alkyl, —CH2C(O)—O-alkyl, —CH2C(O)NH2, —CH2C(O)—NHalkyl or —CH2C(O)—N(alkyl)2; R19 is optionally substituted phenyl, heteroaryl or naphthyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; and R5, R13, R14, R15 and R16 are hydrogen or alkyl for the treatment of HIV, solid organ transplant rejection, graft v.Type: GrantFiled: November 8, 2001Date of Patent: August 5, 2003Assignee: Schering CorporationInventors: Bahige M. Baroudy, John W. Clader, Hubert B. Josien, Stuart W. McCombie, Brian A. McKittrick, Michael W. Miller, Bernard R. Neustadt, Anandan Palani, Ruo Steensma, Jayaram R. Tagat, Susan F. Vice, Mark A. Laughlin
-
Patent number: 6602886Abstract: The small nonpeptides of the instant invention are tachykinin antagonists. The compounds are highly selective and functional NK3 antagonists expected to be useful in the treatment of pain, depression, anxiety, panic, schizophrenia, neuralgia, addiction disorders, inflammatory diseases, gastrointestinal disorders, vascular disorders, and neuropathological disorders.Type: GrantFiled: June 21, 2002Date of Patent: August 5, 2003Assignee: Warner-Lambert CompanyInventors: Michael Huai Gu Chen, Fu-Zon Chung, Helen Tsenwhei Lee
-
Publication number: 20030144323Abstract: Substituted phenylalkynes of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.Type: ApplicationFiled: December 2, 2002Publication date: July 31, 2003Inventors: Richard Apodaca, Wei Xiao, Jill A. Jablonowski
-
Publication number: 20030139446Abstract: In one embodiment, the present invention discloses a process to directly prepare an unequal ratio of specific, preferred rotamer or rotameric pair of an acid salt from a basic compound, by creative choice of a solvent medium. The process is particularly useful in preparing desired rotamers of pharmaceutically useful salts.Type: ApplicationFiled: November 26, 2002Publication date: July 24, 2003Applicant: Schering CorporationInventors: Minzhang Chen, Bosco D'sa, William Leong, Suhan Tang
-
Patent number: 6596724Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of oxadiazole, thiadiazole and thiadiazole oxide derivatives of dihydropyridines of Formula I. wherein B is with X being O, S or and X1 is O or S. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.Type: GrantFiled: July 2, 2001Date of Patent: July 22, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Graham S. Poindexter, Mendi Higgins, James Guy Breitenbucher
-
Publication number: 20030130275Abstract: The invention relates to novel sulphonamide compounds having 5-HT7 antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.Type: ApplicationFiled: November 27, 2002Publication date: July 10, 2003Applicant: SmithKline Beecham p.l.c.Inventor: Peter John Lovell
-
Publication number: 20030114452Abstract: Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.Type: ApplicationFiled: May 17, 2002Publication date: June 19, 2003Applicant: SmithKline Beecham CorporationInventors: Jerry L. Adams, Ralph F. Hall
-
Publication number: 20030105131Abstract: In one embodiment, the present invention describes the synthesis of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl]-4′-methyl-1,4′-bipiperidine, and intermediates therefor from easily available starting materials by a simple route.Type: ApplicationFiled: October 11, 2002Publication date: June 5, 2003Applicant: SCHERING CORPORATIONInventors: Minzhang Chen, Bosco Anthony D'Sa, William W. Leong, Tong Gan, George S.K. Wong, Suhan Tang, Christopher Michael Nielsen
-
Patent number: 6566376Abstract: The invention provides compounds of general formula (I) wherein R1, R2, R3, R4, A, Q, U, V, W, X, Y and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions.Type: GrantFiled: September 8, 2000Date of Patent: May 20, 2003Assignee: AstraZeneca UK LimitedInventors: Andrew J G Baxter, Stephen J Brough, Thomas McInally
-
Patent number: 6548516Abstract: Piperidine derivatives of the formula I and their physiologically acceptable salts in which X, Y, Z, R1, R2, R3 and R4 are as defined in claim 1 can be as excitatory amino acid antagonists for combating neurodegenerative disorders including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's disease, cerebral ischaemias, infarcts and psychosis.Type: GrantFiled: September 14, 2000Date of Patent: April 15, 2003Assignee: Merck Patent GmbHInventors: Helmut Prücher, Joachim Leibrock, Andrew Barber, Gerd Bartoszyk
-
Patent number: 6525069Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.Type: GrantFiled: June 21, 2000Date of Patent: February 25, 2003Assignee: Bristol-Myers Squibb Pharma Co.Inventors: Soo S. Ko, George V. Delucca, John V. Duncia, Ui Tae Kim, Dean A. Wacker, Changsheng Zheng
-
Publication number: 20030036654Abstract: New compounds are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains.Type: ApplicationFiled: February 28, 2002Publication date: February 20, 2003Inventors: Dennis A. Holt, Terence P. Keenan, Tao Guo, Edgardo Laborde, Wu Yang
-
Patent number: 6515130Abstract: A process for preparing a compound of formula I wherein R1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl and halogenType: GrantFiled: March 21, 2000Date of Patent: February 4, 2003Inventors: Judith H. Cohen, Michael Justus, Cynthia A. Maryanoff, Armin Rössler, Fridtjof Schröder, Kirk L. Sorgi, Frank J. Villani, Jr., Christian Weh
-
Publication number: 20030022893Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with matrix metalloproteinase, ADAM or ADAM-TS enzymes, a condition that is mediated by TNF &agr; or a condition involving a membrane-shedding event that is mediated by a metalloproteinase.Type: ApplicationFiled: August 29, 2002Publication date: January 30, 2003Inventors: Andrew Douglas Baxter, David Alan Owen, Duncan Batty, Robert John Watson
-
Patent number: 6511993Abstract: Compounds of formula (I) and pharmaceutically-acceptable derivatives thereof, are matrix metalloprotease inhibitors, useful in treatment of conditions mediated by matrix metalloproteases, such as chronic dermal ulcers.Type: GrantFiled: June 2, 2000Date of Patent: January 28, 2003Inventors: Kevin Neil Dack, Michael Jonathan Fray, Gavin Alistair Whitlock, Mark Llewellyn Lewis, Nicholas Murray Thomson
-
Patent number: 6509464Abstract: Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.Type: GrantFiled: October 30, 2000Date of Patent: January 21, 2003Assignee: Pfizer IncInventors: Martin J. Wythes, Michael J. Palmer, Mark I. Kemp, Malcolm C. MacKenny, Robert J. Maguire, James F. Blake, Jr.
-
Patent number: 6506751Abstract: Disclosed are compounds of the Formula I wherein: Z is C or nothing, provided that when Z is nothing, R3 and R4 are nothing; A is S, S═O or O═S═O; R1 and R2 are independently hydrogen, lower alkyl, halogen, hydroxy or lower alkoxy, (un)substituted aryl, (un)substituted arylalkyl, (un)substituted heteroaryl or(un)substituted heteroarylakyl; R3 and R4 independently represent hydrogen, lower alkyl, cycloalkyl, aminoalkyl, mono- or dialkylaminoalkyl, (un)substituted aryl or (un)substituted heteroaryl; R5 represents a (un)substituted carbocyclic group containing from 3-7 members, up to two of which members are optionally hetero atoms; or R5 is (CR6R7)—(CH2)n—XR8R9; X is S or N; R6, R7, R8, R9, and n are as defined in the specification. The compounds are useful in the treatment and prevention of the AIDS virus. Intermediates useful in the preparation of the final products, pharmaceutical compositions containing the final products are also taught.Type: GrantFiled: November 2, 2000Date of Patent: January 14, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Stephanie Elizabeth Ault Justus, Helen Tsenwhei Lee, Jason Keith Pontrello, Bruce David Roth, Karen Elaine Sexton, Michael William Wilson
-
Publication number: 20030008877Abstract: Compounds of the formula 1Type: ApplicationFiled: March 27, 2002Publication date: January 9, 2003Applicant: Schering CorporationInventor: Michael W. Miller
-
Patent number: RE38257Abstract: A piperidine compound of the formula (I): wherein A is a fused aromatic ring; R is hydrogen, chloro or methoxy; X is (CH2)n, which may be substituted, in which n is 0 or an integer of 1 to 10, —CH≡CH—, —C≡C—, —O—, —S—, —NH—, —N(COCH3)—, —N(COOC2H5)—, —N(CHO)—, —N(CH3)—, —CO—, —SO—, or —SO2—; Y is —CH≡CH—, —CH2CH2—, —CH2CO—, —O—, —S—, —NH—, —OCH2—, —SCH2—, —NHCH2—, —CH(OH)CH2— or —CH(OH)CH(OH)—; and Q is substituted or unsubstituted n-hexyl, carboxypropyl, ethoxycarbonylpropyl, cyanopropyl, cyclohexyl, phenyl, indanyl, naphthyl, tetrahydronaphthyl, benzocycloheptyl, piperidinyl, tetrahydroisoquinolinyl, indolyl, pyrolyl, furyl, thienyl, thiazolyl, oxazolyl or N-methylpyrolyl, wherein any one or more of tType: GrantFiled: February 10, 1999Date of Patent: September 23, 2003Assignee: Ajinomoto Co., Inc.Inventors: Masataka Shoji, Kozo Toyota, Chikahiko Eguchi, Ryota Yoshimoto, Yoshikatsu Koyama, Hideki Domoto, Akira Kamimura